CY1122305T1 - HYDROXAMIC ACID HYDROXAZOLE COMPOUNDS AS LPXC INHIBITORS - Google Patents

HYDROXAMIC ACID HYDROXAZOLE COMPOUNDS AS LPXC INHIBITORS

Info

Publication number
CY1122305T1
CY1122305T1 CY20191101181T CY191101181T CY1122305T1 CY 1122305 T1 CY1122305 T1 CY 1122305T1 CY 20191101181 T CY20191101181 T CY 20191101181T CY 191101181 T CY191101181 T CY 191101181T CY 1122305 T1 CY1122305 T1 CY 1122305T1
Authority
CY
Cyprus
Prior art keywords
compounds
hydroxazole
hydroxamic acid
lpxc inhibitors
lpxc
Prior art date
Application number
CY20191101181T
Other languages
Greek (el)
Inventor
Jiping Fu
Xianming Jin
Subramanian Karur
Guillaume LAPOINTE
Ann Marie Madera
Zachary Kevin Sweeney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1122305T1 publication Critical patent/CY1122305T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Αυτή η εφεύρεση σχετίζεται γενικά με ενώσεις με Τύπο I όπως περιγράφεται στο παρόν και συνθέσεις που περιέχουν αυτές τις ενώσεις, όπως επίσης και μεθόδους χρησιμοποίησης αυτών των ενώσεων για αντιμετώπιση βακτηριακών λοιμώξεων. Σε ορισμένα θέματα, η εφεύρεση παρέχει μεθόδους και συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις για αντιμετώπιση λοιμώξεων που προκαλούνται από αρνητικά κατά Gram βακτήρια.This invention relates generally to compounds of Formula I as described herein and compositions containing these compounds, as well as methods of using these compounds to treat bacterial infections. In certain aspects, the invention provides methods and compositions comprising these compounds for treating infections caused by Gram-negative bacteria.

CY20191101181T 2014-12-16 2019-11-11 HYDROXAMIC ACID HYDROXAZOLE COMPOUNDS AS LPXC INHIBITORS CY1122305T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092402P 2014-12-16 2014-12-16
PCT/IB2015/059631 WO2016097995A1 (en) 2014-12-16 2015-12-15 Isoxazole hydroxamic acid compounds as lpxc inhibitors

Publications (1)

Publication Number Publication Date
CY1122305T1 true CY1122305T1 (en) 2021-01-27

Family

ID=55025302

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101181T CY1122305T1 (en) 2014-12-16 2019-11-11 HYDROXAMIC ACID HYDROXAZOLE COMPOUNDS AS LPXC INHIBITORS

Country Status (41)

Country Link
US (3) US9549916B2 (en)
EP (1) EP3233843B1 (en)
JP (1) JP6697466B2 (en)
KR (1) KR20170094214A (en)
CN (1) CN107001295B (en)
AR (1) AR107428A1 (en)
AU (1) AU2015365455B2 (en)
BR (1) BR112017011422A2 (en)
CA (1) CA2969803A1 (en)
CL (1) CL2017001460A1 (en)
CO (1) CO2017005870A2 (en)
CR (1) CR20170260A (en)
CU (1) CU24443B1 (en)
CY (1) CY1122305T1 (en)
DK (1) DK3233843T3 (en)
EA (1) EA032138B1 (en)
EC (1) ECSP17045737A (en)
ES (1) ES2756300T3 (en)
GT (1) GT201700132A (en)
HR (1) HRP20192009T1 (en)
HU (1) HUE047225T2 (en)
IL (1) IL252373B (en)
JO (1) JO3818B1 (en)
LT (1) LT3233843T (en)
MA (1) MA41185B1 (en)
ME (1) ME03546B (en)
MX (1) MX2017007980A (en)
MY (1) MY195743A (en)
PE (1) PE20171044A1 (en)
PH (1) PH12017501019A1 (en)
PL (1) PL3233843T3 (en)
PT (1) PT3233843T (en)
RS (1) RS59507B1 (en)
SG (1) SG11201704053WA (en)
SI (1) SI3233843T1 (en)
SV (1) SV2017005462A (en)
TN (1) TN2017000207A1 (en)
TW (1) TWI693215B (en)
UA (1) UA121225C2 (en)
UY (1) UY36448A (en)
WO (1) WO2016097995A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3786162T3 (en) 2013-05-17 2023-10-02 Incyte Holdings Corp Bipyrazole derivatives as jak inhibitors
DK3468957T3 (en) * 2016-06-14 2020-09-14 Novartis Ag CRYSTALLIC FORM OF (R) -4- (5- (CYCLOPRO PYLETHYNYL) ISOXAZOL-3-YL) -N-HYDROXY-2-METHYL-2- (METHYLSULPHONYL) BUTANAMIDE AS AN ANTIBACTERIAL
CN107434766A (en) * 2017-08-09 2017-12-05 凯莱英医药集团（天津）股份有限公司 The synthesizer and method for continuously synthesizing of alkane hydroxylamine compound
MX2020008521A (en) 2018-02-16 2020-12-03 Incyte Corp Jak1 pathway inhibitors for the treatment of cytokine-related disorders.
JPWO2020105660A1 (en) * 2018-11-21 2021-09-30 大正製薬株式会社 New imidazole derivative
KR20230027086A (en) 2020-06-02 2023-02-27 인사이트 코포레이션 Manufacturing process of JAK1 inhibitor
KR20230118118A (en) 2020-12-08 2023-08-10 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of vitiligo
CN112603936B (en) * 2020-12-28 2022-08-02 仲恺农业工程学院 Composition for inhibiting aeromonas, preparation method and application thereof
WO2022173758A1 (en) * 2021-02-11 2022-08-18 Forge Therapeutics, Inc. Antibacterial compounds
WO2022173756A1 (en) * 2021-02-11 2022-08-18 Forge Therapeutics, Inc. Antibacterial compounds
TW202322818A (en) * 2021-09-28 2023-06-16 美商福吉醫療公司 Lpxc inhibitors and uses thereof
WO2024067812A1 (en) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 Aromatic acetylene derivative, preparation method therefor, and use thereof
WO2024067813A1 (en) * 2022-09-28 2024-04-04 浙江海正药业股份有限公司 Aromatic acetylene derivative, preparation method therefor, and pharmaceutical use thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381783D1 (en) 1982-03-03 1990-09-13 Genentech Inc HUMAN ANTITHROMBIN III, DNA SEQUENCES THEREFOR, EXPRESSION AND CLONING VECTORS CONTAINING SUCH SEQUENCES AND THEREFORE TRANSFORMED CELL CULTURES, METHOD FOR EXPRESSING HUMAN ANTITHROMBIN III AND THESE CONTAINERS.
EP0418667B1 (en) 1989-09-22 1995-08-16 BASF Aktiengesellschaft Carboxylic acid amides
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1947183B1 (en) 1996-08-16 2013-07-17 Merck Sharp & Dohme Corp. Mammalian cell surface antigens; related reagents
US6509173B1 (en) 1997-10-21 2003-01-21 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
JP2002502607A (en) 1998-02-09 2002-01-29 ジェネンテク・インコーポレイテッド Novel tumor necrosis factor receptor homologs and nucleic acids encoding the same
EP1196186B1 (en) 1999-07-12 2007-10-31 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
US7521051B2 (en) 2002-12-23 2009-04-21 Medimmune Limited Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
CA2851462A1 (en) * 2003-01-08 2004-07-29 University Of Washington Antibacterial agents
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
MXPA05012475A (en) 2003-05-23 2006-05-25 Wyeth Corp Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof.
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
JP2007518399A (en) 2003-12-02 2007-07-12 ジェンザイム コーポレイション Compositions and methods for diagnosing and treating lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
WO2006083289A2 (en) 2004-06-04 2006-08-10 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
GB0502418D0 (en) 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
PT2343320T (en) 2005-03-25 2018-01-23 Gitr Inc Anti-gitr antibodies and uses thereof
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
HUE026039T2 (en) 2005-07-01 2016-05-30 Squibb & Sons Llc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1981969A4 (en) 2006-01-19 2009-06-03 Genzyme Corp Gitr antibodies for the treatment of cancer
SI2170959T1 (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP3124046B1 (en) 2007-07-12 2019-12-25 GITR, Inc. Combination therapies employing gitr binding molecules
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme Pd-1 binding proteins
EP2310508A1 (en) 2008-07-02 2011-04-20 Emergent Product Development Seattle, LLC Tgf-b antagonist multi-target binding proteins
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
PE20110435A1 (en) 2008-08-25 2011-07-20 Amplimmune Inc ANTAGONIST COMPOSITIONS OF PD-1
AU2009288289B2 (en) 2008-08-25 2012-11-08 Amplimmune, Inc. PD-1 antagonists and methods of use thereof
WO2010030002A1 (en) 2008-09-12 2010-03-18 国立大学法人三重大学 Cell capable of expressing exogenous gitr ligand
JP5524215B2 (en) * 2008-09-19 2014-06-18 ファイザー・インク Hydroxamic acid derivatives useful as antibacterial agents
CN114835812A (en) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 anti-PD-L1 antibodies and their use for enhancing T cell function
EP3192811A1 (en) 2009-02-09 2017-07-19 Université d'Aix-Marseille Pd-1 antibodies and pd-l1 antibodies and uses thereof
ES2788869T3 (en) 2009-09-03 2020-10-23 Merck Sharp & Dohme Anti-GITR antibodies
JP5671545B2 (en) * 2009-10-13 2015-02-18 ファイザー・インク C-bonded hydroxamic acid derivatives useful as antibacterial agents
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc Simultaneous inhibition of pd-l1/pd-l2
SI2512474T1 (en) * 2009-12-16 2014-12-31 Pfizer Inc. N-linked hydroxamic acid derivatives useful as antibacterial agents
EP2519544A1 (en) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptide heterodimers and uses thereof
US8877754B2 (en) 2010-09-06 2014-11-04 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
CN103298780A (en) 2010-11-10 2013-09-11 尔察祯有限公司 Hydroxamic acid derivatives and their use in the treatment of bacterial infections
EP2683689B1 (en) 2011-03-07 2017-04-12 Pfizer Inc Fluoro-pyridinone derivatives useful as antibacterial agents
WO2012137094A1 (en) 2011-04-08 2012-10-11 Pfizer Inc. Isoxazole derivatives useful as antibacterial agents
EP2694481B1 (en) * 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
AU2012344260B2 (en) 2011-11-28 2017-09-07 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
WO2014160649A1 (en) 2013-03-29 2014-10-02 Novartis Ag Hydroxamic acid derivatives as lpxc inhibitors for the treatment of bacterial infections

Also Published As

Publication number Publication date
CU20170084A7 (en) 2017-11-07
SI3233843T1 (en) 2019-12-31
TWI693215B (en) 2020-05-11
US10029994B2 (en) 2018-07-24
AU2015365455B2 (en) 2019-01-17
CO2017005870A2 (en) 2017-10-20
ES2756300T3 (en) 2020-04-27
EA201791353A1 (en) 2017-10-31
CR20170260A (en) 2017-08-21
WO2016097995A1 (en) 2016-06-23
HRP20192009T1 (en) 2020-02-07
CN107001295B (en) 2021-02-02
AR107428A1 (en) 2018-05-02
HUE047225T2 (en) 2020-04-28
MA41185B1 (en) 2019-12-31
PH12017501019B1 (en) 2017-12-04
GT201700132A (en) 2019-10-10
IL252373B (en) 2019-11-28
ECSP17045737A (en) 2019-02-28
KR20170094214A (en) 2017-08-17
TN2017000207A1 (en) 2018-10-19
SG11201704053WA (en) 2017-06-29
PH12017501019A1 (en) 2017-12-04
MY195743A (en) 2023-02-08
EA032138B1 (en) 2019-04-30
US20160166548A1 (en) 2016-06-16
JP6697466B2 (en) 2020-05-20
CU24443B1 (en) 2019-10-04
JO3818B1 (en) 2021-01-31
PT3233843T (en) 2019-11-26
CN107001295A (en) 2017-08-01
BR112017011422A2 (en) 2018-04-03
US9815804B2 (en) 2017-11-14
EP3233843A1 (en) 2017-10-25
JP2018500333A (en) 2018-01-11
SV2017005462A (en) 2018-04-04
PE20171044A1 (en) 2017-07-19
MX2017007980A (en) 2017-09-29
US20180030004A1 (en) 2018-02-01
EP3233843B1 (en) 2019-10-16
CA2969803A1 (en) 2016-06-23
AU2015365455A1 (en) 2017-06-08
PL3233843T3 (en) 2020-04-30
DK3233843T3 (en) 2019-11-18
UA121225C2 (en) 2020-04-27
LT3233843T (en) 2019-12-10
US9549916B2 (en) 2017-01-24
TW201629024A (en) 2016-08-16
ME03546B (en) 2020-07-20
CL2017001460A1 (en) 2017-12-22
UY36448A (en) 2016-07-29
US20170088525A1 (en) 2017-03-30
IL252373A0 (en) 2017-07-31
RS59507B1 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
CY1122305T1 (en) HYDROXAMIC ACID HYDROXAZOLE COMPOUNDS AS LPXC INHIBITORS
CY1121701T1 (en) ORGANIC MONOBACTAM COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
EA201691534A1 (en) TREATMENT OF SUSTAINABLE UGRAI
EA201792205A1 (en) HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
EA201391072A1 (en) FLUORIN-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS
EA201691794A1 (en) CONDENSED [1,4] DIAZEPIN COMPOUNDS AS AUTOTAXIN (ATX) PRODUCT INHIBITORS AND LIZOPHOSPHATIDYLIC ACID (LPA) INHIBITORS
EA201690406A1 (en) GRP94 SELECTIVE INHIBITORS AND METHODS OF THEIR APPLICATION
EA201692114A1 (en) SUBSTITUTED DIHYDRO-ISOHINOLINE NON COMPOUNDS
EA201491970A1 (en) CYCLIC BRIDGES SIMPLE ETHERS AS DGAT1 INHIBITORS
EA201690844A1 (en) GSK-3 INHIBITORS
EA201890331A1 (en) PYRIDINODICARBOXAMIDES FOR APPLICATION AS BROMODOUM INHIBITORS AS
EA201790576A1 (en) Spirocyclic inhibitors of katepsin C
MX2017012073A (en) Minocycline compounds for biodefense.
CR20170050A (en) AZETIDINYLOXYPHENYLPIRROLIDINE COMPOUNDS
EA201690227A1 (en) AZAINDOL COMPOUNDS, THEIR PRODUCTION AND METHODS OF THEIR APPLICATION
MX2018016339A (en) Anti-infective heterocyclic compounds and uses thereof.
EA201491581A1 (en) ВЕЗИКУЛЯРНЫЕ КОМПОЗИЦИИ
EA201590331A1 (en) NEW ANTIBACTERIAL CONNECTIONS
EA201690561A1 (en) Peptidylnitrile compounds as inhibitors of dipopeptidyl peptidase I
EA201500737A1 (en) PYRAZOLILKARBOXAMIDA II AS CRAC CHANNEL INHIBITORS
EA201500736A1 (en) PYRAZOLILKARBOXAMIDA I AS CRAC CHANNEL INHIBITORS
EA202090750A1 (en) GLUCONIC ACID DERIVATIVES FOR USE IN TREATMENT AND / OR PREVENTION OF INFECTIONS CAUSED BY MICROORGANISMS
EA201590729A1 (en) DERIVATIVES OF 3,4-DISABILIZED OXIAZOLIDINONONE AND THEIR APPLICATION AS CALCIUM ACTIVATED POTASSIUM CHANNEL INHIBITORS
CY1119316T1 (en) Hydrochloride Salts of an Antibiotic Union
EA202090336A1 (en) COMPOUNDS, THEIR SALTS AND METHODS FOR TREATING DISEASES